- Home
- TBPH
as 07-05-2024 4:00pm EST
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
| Founded: | N/A | Country: | Cayman Islands |
| Employees: | N/A | City: | GEORGE TOWN, GRAND CAYMAN |
| Market Cap: | 409.0M | IPO Year: | N/A |
| Target Price: | $20.50 | AVG Volume (30 days): | 337.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.13 - $11.71 | Next Earning Date: | 08-05-2024 |
| Revenue: | $61,510,000 | Revenue Growth: | 26.65% |
| Revenue Growth (this year): | 28.74% | Revenue Growth (next year): | 12.12% |
Stock Insider Trading Activity of Theravance Biopharma Inc. (TBPH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Samaha Eli | TBPH | 10% Owner | May 1 '24 | Buy | $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | SEC Form 4 |
| Samaha Eli | TBPH | 10% Owner | May 1 '24 | Buy | $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | SEC Form 4 |
| Farnum Rhonda | TBPH | SVP, COMM & MEDICAL AFFAIRS | Feb 20 '24 | Sell | $8.71 | 1,254 | $10,922.34 | 311,733 | SEC Form 4 |
| Farnum Rhonda | TBPH | SVP, COMM & MEDICAL AFFAIRS | Nov 20 '23 | Sell | $10.29 | 1,378 | $14,179.62 | 331,206 | SEC Form 4 |
Latest Theravance Biopharma Inc. News
TBPH Breaking Stock News: Dive into TBPH Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Investors in Theravance Biopharma (NASDAQ:TBPH) have unfortunately lost 52% over the last five years
Zacks
10 days ago
Here's Why You May Invest in Theravance (TBPH) Stock Now
Zacks
15 days ago
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
Zacks
24 days ago
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
ACCESSWIRE
25 days ago
Sidoti Events, LLC's Virtual June Small-Cap Conference
Simply Wall St.
a month ago
High Insider Ownership Growth Companies On US Exchange May 2024
Simply Wall St.
2 months ago
Theravance Biopharma First Quarter 2024 Earnings: Beats Expectations
Zacks
2 months ago
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Share on Social Networks:
Disclaimer
The information presented on this page, "TBPH Theravance Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.